Adc Therapeutics Sa stock is traded at $1.64, with a volume of 1,723,852. It is down -4.65% in the last 24 hours and up +33.33% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Previous Close:
$1.72
Open:
$1.73
24h Volume:
1,723,852
Relative Volume:
1.23
Market Cap:
$209.38M
Revenue:
$79.18M
Net Income/Loss:
-$136.99M
P/E Ratio:
-
EPS:
-$1.05
Net Cash Flow:
-$120.11M
1W Performance:
+10.07%
1M Performance:
+33.33%
6M Performance:
-56.38%
1Y Performance:
-59.00%
1-Day Range:
$1.61$1.74
1-Week Range:
$1.50$1.87
52-Week Range:
$0.7796$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS